Evidence map›Paper›PMID 28614668›Full record

ArticleAmerican journal of respiratory and critical care medicine2017

Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

John Z Metcalfe, Elizabeth Streicher, Grant Theron, Rebecca E Colman, Christopher Allender, Darrin Lemmer, Rob Warren, David M Engelthaler

Abstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Mixed infections and heteroresistance ofEmerging microbes & infections · 2025
    Article
  4. Whole-Genome Sequence-Based Diversity ofPathogens (Basel, Switzerland) · 2025
    Article
  5. Xpert MTB/RIF Ultra-resistant and MTBDRAntimicrobial agents and chemotherapy · 2025
    Article
  6. Impact of repeatedFrontiers in microbiology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Genomic markers of drug resistance inJournal of clinical microbiology · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. MinorityAmerican journal of respiratory cell and molecular biology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

John Z Metcalfe1 Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California.
Elizabeth Streicher2 DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Grant Theron2 DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.ORCID 0000-0002-9216-2415
Rebecca E Colman3 Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, San Diego, San Diego, California; and.
Christopher Allender4 Translational Genomics Research Institute, Flagstaff, Arizona.
Darrin Lemmer4 Translational Genomics Research Institute, Flagstaff, Arizona.
Rob Warren2 DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
David M Engelthaler4 Translational Genomics Research Institute, Flagstaff, Arizona.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMinority drug-resistant Mycobacterium tuberculosis subpopulations can be associated with phenotypic resistance but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays.

objectivesTo determine the role of targeted next-generation sequencing in resolving these minor variant subpopulations.

methodsWe used single molecule overlapping reads (SMOR), a targeted next-generation sequencing approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance-determining regions (study group). Isolates also underwent single-colony selection on antibiotic-containing agar, blinded to sequencing results. As a positive control, isolates with multiple colocalizing chromatogram peaks were also analyzed (control group). MEASUREMENTS AND MAIN

resultsAmong 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49%) and 45 (33%) of 135 total heteroresistant RAVs at frequencies less than 5% and less than 1% of the total mycobacterial population, respectively. In the study group, SMOR detected minor resistant variant subpopulations in 80% (n = 20/25) of isolates with no Sanger-identified RAVs (median subpopulation size, 1.0%; interquartile range, 0.2-3.9%). Single-colony selection on drug-containing media corroborated SMOR results for 90% (n = 18/20) of RAV-containing specimens, and the absence of RAVs in 60% (n = 3/5) of isolates. Overall, Sanger sequencing was concordant with SMOR for 77% (n = 53/69) of macroheteroresistant (5-95% total population), but only 5% of microheteroresistant (<5%) subpopulations (n = 3/66) across both groups.

conclusionsCryptic minor variant mycobacterial subpopulations exist below the resolving capability of current drug susceptibility testing methodologies, and may explain an important proportion of false-negative resistance determinations.

Indexed as

Drug Resistance, BacterialMicrobial Sensitivity TestsMycobacterium tuberculosisSequence Analysisdiagnosticsdrug-resistant tuberculosisnext-generation sequencingSanger sequencing

Identifiers

PMID28614668
PMCPMC5694839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.